. Percentage and number of CD34 þ cells were 0.3770.13% and 3.971.2 Â 10 6 . After separation, CD34 þ cell purity was 82711%. Mean number of inoculated cells was 760 000; mean NC and CD34 þ fold expansion at 12 days was 230.4791.5 and 21.0711.9. Both groups of mice showed successful engraftment: the percentage of human cells was higher in the group receiving expanded cells (3.472.01%) compared to the group receiving nonexpanded cells (1.570.66%) (Po0.00018, Mann-Whitney test). The cell population obtained after 12 days expansion consisted mainly of myeloid and megakaryocytic progenitors. The CD34 þ antigen reached the maximum expression level at day 12 (7.572.0%). Analysis of lineage-markers for human myelomonocytic, megakaryocytic, B, T, CD34 and erythroid cells, gave evidence that all the lineages were represented in the marrow of transplanted mice. 1,2 Since the first unrelated umbilical cord blood transplants (UCBT), more than 3500 UCBT, have been performed worldwide. 3 The majority of the procedures has occurred in a paediatric setting using cord blood units that have been collected and stored in banks around the world. The best predictor of event free survival (EFS) in UCB recipients is the cell dose transplanted, with a distinct survival advantage seen in patients that received more than 3 Â 10 7 total nucleated cells/kg. [4] [5] [6] [7] To overcome the limitations of cell number, over the past 15 years many patients have been transplanted with ex vivo expanded cells from UCB, peripheral blood (PB), bone marrow (BM), and clinical trials have demonstrated the safety and feasibility of the expansion procedures. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Ex vivo expansions have been performed using different expansion chambers, reagents and procedures (ie commercial tissue culture flask, culture bags, bioreactors or dedicated devices with different growth factor combinations, culture conditions, in presence or absence of serum from animal sources). Moreover, the expansions have been performed using both unselected or selected CD34 þ cells. All these expansion procedures have been performed by extremely well equipped laboratories, by means of skilled scientists and technicians. Most of the procedures utilized until now in a clinical setting have not used certified reagents and devices. Previous studies from several groups have demonstrated that HSC cells can be expanded in defined culture conditions, in the absence of stroma layers in serum-free media and in the absence of animal derived products: [19] [20] [21] [22] [23] [24] In the present study, seven fresh and three cryopreserved UCB samples were ex vivo expanded in the Dideco 'Pluricell System', following the manufacturer's instructions. The total nucleated (NC), CD34 þ cell number and phenotype after 12 days of expansion have been evaluated.
The animal model system available to analyse engraftment capability of HSC is represented by transplant of HSC in sublethally irradiated severe combined immunodeficient and nonobese diabetic (NOD/SCID) mice. The analysis of human haematopoietic cells in the BM of the animals is performed 6-8 weeks after the transplant. 25 The detection of a percentage of human cells greater than 0.1% in the BM of transplanted animals demonstrates that the transplanted human cells homed to and engrafted the murine BM, where they proliferate and differentiate to produce immature and mature myeloid, erythroid and lymphoid cells. 26 The engrafted human cells have been defined as SCID-repopulating cells (SRC). 27, 28 The abovedescribed NOD/SCID animal model system represents the in vivo repopulating potential of HSC. With the aim to investigate if the human UCB CD34 þ cells ex vivo expanded in the Dideco 'Pluricell System' maintain their capability to engraft the murine BM, we have transplanted two groups of irradiated NOD-SCID mice respectively with expanded and nonexpanded cells derived from the same UCB. After 6 weeks, mice BM have been collected and analysed for the presence of human cells.
Materials and methods

Short description of the device
The Dideco 'Pluricell System' is a commercially available CE-marked device (Pat. Pend.) that allows HSC expansion in a closed system. It is composed of a 175 cm 2 polystyrene expansion chamber equipped with sterilizing filters for the injection of the culture media, a vented filter for gas exchange, two injecting sites for cell inoculum and sampling and a system of bags and filters for the final washing and recovery of the expanded cellular product accordingly to cGTP. 29 The expansion chamber and the bags are certified sterile and pyrogen-free. The system includes a ready-to-use kit of certified reagents (serum-free media and a balanced mixture of Flt-3L, TPO, IL-3, SCF, growth factors known to induce expansion of HSC in vitro [30] [31] [32] [33] [34] [35] ). All the reagents do not contain animal derivatives and are certified sterile, mycoplasma and endotoxin free.
UCB collection
Three cryopreserved and seven fresh UCB samples were processed. The cryopreserved samples were processed following the Rubinstein's protocol. 36 The fresh samples were collected from normal full-term delivery placentas: blood was drained in sterile flasks containing 10 ml of citrate phosphate dextrose adenine (CPD-A) and 500 IU of heparin (Clarisco Forte, Schwarz Pharma, Milano). After collection, UCB samples were stored at room temperature and processed within 24 h. The above protocol was approved by the local ethical committee and informed consent was obtained prior to collection.
CD34 þ cells purification
Cryopreserved units were placed in gas phase of liquid nitrogen for 30 min, then moved to room temperature for 5 min and finally quickly thawed in a 381C water bath; the bags were then transferred to a laminar flow hood and a solution containing 6% Dextran 40 (ICN Biomedicals, Eschwege, Germany), þ 5% v/v Human Albumin (Grifols, Barcelona, Spain) was added. Samples were then transferred in a 225 ml tube and centrifuged at 1600 rpm for 10 min at 101C. The supernatant was removed, and the sediment resuspended in Hank's Balanced Salt Solution (Sigma-Aldrich, Milano, Italy). Mononuclear cells (MNC) were isolated from UCB samples by density gradient centrifugation with Lympholyte-H (Cedarlane Laboratories Limited, Hornby, Canada). The CD34 þ cells were purified using the MACS CD34 Progenitor Cell Isolation Kit (Miltenyi Biotec GmbH; Bergisch Gladbach, Germany) following the manufacturer's protocol. The final elution of the selected cells from the column was performed in 5 ml of X-VIVO 20 cell culture medium (Cambrex, New Jersey, USA). Cell number and viability were evaluated by trypan blue exclusion test using a Neubauer cell counting chamber. HSC purity was determined by FACS analysis.
For the NOD-SCID mice experiment, the CD34 þ cell fraction from one UCB sample was divided in two aliquots: 1 500 000 cells were cryopreserved while 760 000 were ex vivo expanded in the Dideco 'Pluricell System'. The CD34 þ depleted fraction of the MNC cells was also collected and cryopreserved: these cells were used as carrier cells upon irradiation as described below. Both CD34 þ purified cells and CD34À carrier cells were resuspended in X-VIVO 20 and transferred into 2 ml cryovials (Nalgene, Rochester, NY, USA). The cryopreservative solution was prepared by mixing nine parts of foetal calf serum (FCS) and one part of dimethylsulphoxide, DMSO (SigmaAldrich). Samples were stored into a liquid nitrogen tank. Before inoculating mice, the nonexpanded CD34 þ cells were thawed, counted and the viability assessed by trypan blue. Viable cells (100 000) were aliquoted in sterile Eppendorf 1.5 ml tubes (Eppendorf, Hamburg, Germany) and mixed with 500 000 carrier cells that were previously thawed, resuspended in X-VIVO 20, counted and irradiated at 30Gy using a 137 Cs source. Cells were then injected in the tail lateral vein of the mice.
Ex vivo expansion of CD34 cells
CD34 þ purified cells were expanded in the Dideco 'Pluricell System' (Dideco srl, Mirandola, Italy) following the manufacturer's instructions. Briefly, 'complete medium' ('Med-A' vial added with 5% v/v human plasma and 'CK Mix-A' vial) was injected in the expansion chamber through the 'Day 0 port' equipped with a 0.2 mM sterilizing filter. The CD34 þ purified cells were then injected in the chamber through the 'Cells' port at a final concentration of 20 000 cells/ml in the 'complete medium'. Cultures were incubated at 371C in a fully humidified atmosphere of 5% v/v CO 2 for 12 days and fed after 7 days via the 'Day 7' port (equipped with a 0.2 mM sterilizing filter) by adding fresh 'complete medium' (the whole content of 'Med-B' vial added with 5% v/v of human AB plasma and the 'CK Mix-B' vial). At days 7, 10 and 12 of culture, cells were sampled through the 'Sampling port' and total cell number and viability were evaluated by trypan blue exclusion test using a Neubauer cell count chamber. The expansion values represents the fold increase over the cell starting number.
Animals
NOD/LtSz scid/scid (NOD/SCID) mice were obtained from and maintained in the animal facility of the Istituto Ex vivo expansion in the Dideco 'Pluricell System' G Astori et al Nazionale per la Ricerca sul Cancro (Genova, Italy). The well-being and state of health of experimental animals were controlled by the veterinarian to prevent pain or avoidable suffering, distress or lasting harm. All animals were handled under sterile conditions and maintained in cage microisolators. Mice, at 7 weeks old, to be transplanted were total body irradiated at 300 cGy using a 137 Cs source. A first group of mice was injected with 100 000 viable nonexpanded CD34 þ cells mixed with 500 000 CD34À irradiated carrier cells, and a second group with 15.2 Â 10 6 expanded cells (four and five mice respectively). The number of expanded cells injected was obtained by multiplying 100 000 for the fold increase of the NC after the ex vivo expansion of the sample. Controls were represented by four groups of mice as follows: one unmanipulated, nonirradiated mouse; two irradiated mice injected with 500 000 CD34À carrier cells; four irradiated noninjected mice; two nonirradiated mice injected with 500 000 CD34À carrier cells.
All mice received acidified water containing 1.1 g/l neomycin sulphate and 131 mg/l of polymixin B ad libitum (both from Sigma-Aldrich). Mice were killed 6 weeks post transplant.
Flow cytometry analysis of expanded cells
The CD34 antigen was assessed following the ISHAGE protocol. 37 Briefly, cells were double stained with anti-CD45 FITC and anti-CD34 PE-conjugated antibodies (2D1 and anti-HPCA-2 clones respectively, Becton Dickinson, San Jose, CA, USA). Expression of the other haematopoietic lineage-associated surface antigens was evaluated by double staining the cells with anti-CD61 FITC and anti-CD33 PE. Analyses were performed using a FACScan flow cytometer (Becton Dickinson) acquiring at least 100 000 events. Isotype-matched murine PE and FITC conjugated immunoglobulins were used as controls (all the antibodies were from Becton Dickinson).
Flow cytometric analysis of cells in murine BM
Mouse BM cells were flushed from the femurs of each animal with 2 ml of phosphate buffered saline (PBS) at pH 7.4 using a syringe. Cells were preincubated for 5 0 with 0.25 mg/10 6 cells of purified anti-mouse CD16/CD32 (Fc Block, Becton Dickinson) and then stained with 20 ml of antibodies specific for human CD45-FITC/murine CD45-PE, CD45-FITC/CD19-PE, CD45-FITC/CD34-PE, CD45-FITC/CD33-PE, CD45-FITC/CD61-PE, CD45-FITC/ CD2-PE, CD71FITC/glycophorin-A-PE for 15 min at 201C. Contaminating red blood cells were lysed by using the Facs Lysing Solution (Becton Dickinson) and the remaining cells were washed with PBS/0.5% BSA/0.5% paraformaldehyde. Cells were also incubated with irrelevant isotype control antibodies FITC and PE labelled (all the antibodies were from Becton Dickinson).
Analysis of lineage markers CD19, CD34, CD33, CD61, CD2 were expressed as a percentage of positive cells within the CD45 gate (R1). Analysis of CD71/glycophorin-A positive cells was performed on total BM cells.
Cells from unmanipulated NOD-SCID control mouse were also incubated with the monoclonal antibodies described. Only levels of fluorescence that excluded 99% of this negative control were considered as specific staining. At least 100 000 events were acquired.
Flow cytometric analyses were independently performed by the Immunology and Genetics Laboratory, IRCCS-IOR, Bologna (Italy), using a FACSvantage cytometer (Becton Dickinson).
Results
The expansion procedure after cell selection was performed by the following steps: inoculation of the medium and cells at the beginning of the cultures, addition of fresh medium a week later and harvest of the cellular product after 12 days. All manipulations were carried out by using dedicated ports or circuits allowing a closed system procedure.
The results obtained after the collection, manipulation and expansion of seven fresh UCB samples, can be summarized as follows: the average volume of the seven UCB collected was 61.678.8 ml; the mean content of NC was 1090.57189.9 Â 10 6 (mean7s.d.). The percentage and the number of CD34 þ cells were 0.3770.13 and 3.971.2 Â 10 6 respectively. After immunomagnetic separation, purity obtained was 82711% (range 65.2-93.3). The mean number of inoculated cells was 760 000 (range 680 000-800 000) and the mean volume of 'complete medium' was 38 ml (range 34-40 ml). The mean NC and CD34 þ fold expansion at 12 days was 230.4791.5 and 21.0711.9, respectively. Expression of differentiation antigens at 0, 10 and 12 days is reported in Table 1 .
The results obtained by expanding three cryopreserved UCB samples were as follows: the mean number of CD34 þ cells inoculated in the Dideco 'Pluricell System' was 700 000 (range 500 000-800 000). The mean fold expansion of NC after 12 days was 249.1749.5 and the CD34 þ HSC fold expansion after 12 days was 33.0714.3. Both the NC and the CD34 þ fold expansion data observed by expanding HSC from cryopreserved UCB units with the Dideco 'Pluricell System' are comparable with the results obtained by expanding fresh UCB units. Complete data are reported in Table 2 .
No evidence of bacterial or fungal contamination of the cellular product was observed during the culture period.
NOD-SCID results
The NC and CD34 þ fold expansion for UCB cells used in the NOD-SCID experiment were 152 Â and 9.3 Â respectively. The schematic representation of the experimental groups and controls is reported in Table 3 . The analysis of 
Discussion
Large-scale CD34 þ haematopoietic stem cell expansion is crucial for therapeutic applications; the Dideco 'Pluricell System' is a CE marked commercially available device that allows UCB-HSC expansion in a closed and defined system. It comprises a cell expansion chamber, a reagent kit that does not contain animal derivatives and a system of bags to wash the final cellular product.
We have ex vivo expanded in the Dideco 'Pluricell System' seven fresh and three cryopreserved UCB samples following the manufacturer's instructions: after 12 days, total CD34 þ and NC fold increase was 21.0711.9 and 230791.5 for the fresh UCB samples, respectively; 33.0714.3 and 249749.5 for the cryopreserved UCB samples, evidencing a better cell expansion using cryopreserved samples.
The cell product obtained after 12 days of ex vivo expansion, as evidenced by the expression of the differentiation antigens, is constituted for the most part of myeloid and megakaryocytic progenitors. During the culture time, an increase in the percentage of megakaryocytic progenitors from 11.578.7% at day 10 to 24.3712.1% at day 12 and a slight decrement from 77.076.8% to 67.40712.0% of the myeloid progenitors can be observed. The CD34 þ antigen reached the maximum level of expression at day 12 (7.572.0%).
We tested the ability of the expanded cells to successfully engraft the BM of sublethally irradiated NOD/SCID mice: the mean percentage of engraftment in the group of mice transplanted with expanded cells was 2.3 times higher than in nonexpanded group: this suggest that engraftment capacity after cell expansion was maintained, underlying the ability of ex vivo expanded HSC to engraft a myeloablated recipient.
Analysis of the lineage markers for human myelomonocytic, megakaryocytic, B, T, CD34 and erythroid cells gave evidence that all the lineages were represented in the BM of the mice transplanted with expanded cells, even if a significant decrement in the percentage of human CD19 and CD61 cells in the BM of this group of mice was observed (Po0.01 and o0.05, respectively, Student's t-test). In order to ensure the complete clearance of the residual cytokines from the cell product after expansion, the Pluricell system contains a washing kit including one collection bag and two preconnected waste bags. At the end of the expansion period, the expanded cells are transferred from the expansion chamber to the collection bag using a sterile connection device. We quantified the residual amount of each cytokine after expansion in one UCB sample using ELISA methods; the cell recovery and viability after washing were also determined by sampling cells at the end of the washing procedure. The results of the assays showed that the amount of the residual cytokines in the final product was undetectable; the cell recovery after washing was 83%78.2 (mean7s.d., n ¼ 5) with a mean cell viability of 95% (data not shown). No bacterial or fungal contaminations were observed during the expansion and the washing steps in all the procedures performed.
The Dideco 'Pluricell System' allows an UCB-HSC expansion resulting in a final cell product constituted of committed progenitor cells where the CD34 þ cell population is still represented: this cell population, once injected in sublethally irradiated NOD/SCID mice, retained the ability to successfully engraft murine BM. In conclusion, the Dideco 'Pluricell System' allows an efficient scale-up of UCB ex vivo expansion; moreover, the use of a CE-marked device provided with certified reagents could facilitate the use of expanded cells in the clinical setting. 
